“Unveiling the Success: A Look at Inventiva’s Half-Year Liquidity Contract with Kepler Cheuvreux”
Inventiva Announces Half-Year Report of Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 24, 2025 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs, has…